Adverse effects of transfusions caused by leukocytes

Journal of Intravenous Nursing

Volumn 20, Issue 5, 1997, Pages 238-244

  Raife, Thomas J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CYTOMEGALOVIRUS INFECTION; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; LEUKOCYTE; LUNG INJURY; REVIEW; VIRUS TRANSMISSION;

BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; CYTOKINES; CYTOMEGALOVIRUS INFECTIONS; FEVER; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTES;

EID: 0030866121     PISSN: 08965846     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Intracellular compartments and protein sorting. In: Molecular Biology of the Cell. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD, eds. New York: Garland Publishing Inc., 1994:551-98.
2. Aye MT, Palmer DS, Giulivi A, Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995;35:117-24.
3. Dzik WH. Leukoreduced blood components: laboratory and clinical aspects. In: Principles of Transfusion Medicine. Rossi EC, Simon TL, Moss GS, Gould SA, eds. Baltimore: Williams & Wilkins, 1996:353-73.
4. AABB: Standards for Blood Banks and Transfusion Services. American Association of Blood Banks, 1996:71-6.
5. Technical Manual. American Association of Blood Banks Bethesda 1996:543-90.
6. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JN. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and Primary HLA alloimmunization: a prospective, randomized trial. Blood 1991; 1:201-5.
7. Saarinen UM, Kekomaki R, Siimes MA, Myllyla G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75:512-7.
8. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion 1991;31:588-94.
9. Schiffer CA. Prevention of alloimmunization against platelets. Blood 1991;77:1-4.
10. Slichter S. Trial to reduce alloimmunization to platelets (TRAP) trial study group. Leukocyte-reduction end UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. NEJM 1997 (in press).
11. Rosenthal KS. Human herpesviruses. In: Medical Microbiology. Murray PR, Kobayashi GS, Pfatter MA, Rosenthal KS, eds. St. Louis: Mosby, 1994:571-94.
12. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86: 3598-603.
13. Przepiorka D, LeParc GF, Werch J, Lichtiger B. Prevention of transfusion-associated cytomegalovirus infection-practice parameter. Am J Clin Pathol 1996;106:163-9.
14. Leitman SF, Holland PV. Irradiation of blood products: indications and guidelines. Transfusion 1985;25:293-302.
15. Blumberg N, Heal J. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Am J Med 1996;101:299-307.
16. Duffy G, Neal K. Differences in post-operative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomized and nonrandomized studies. Transfus Med 1996;6:325-8.
17. Dzik S, Blajchman MA, Blumberg N, Kirkley SA, Heal JM, Wood K. Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang 1996;70:187-94.
18. Lee T, Donegan E, Slichter S, Busch MP. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 1995;85:1207-14.